Document is current
Any future updates will be listed below
-
Authors
Jones, Douglas
Narsipur, Nihal https://orcid.org/0009-0004-5183-9153
Wade, Sally W.
Harper, Joseph R.
Park, Nami
Adams, Philippe
Relan, Anurag
Harrington, Amanda
Anderson, John
-
Funding
Funding for this research was provided by:
Pharming Healthcare, Inc.
- License Information
-
More Information
Article History
Received: 14 November 2025
Accepted: 15 December 2025
First Online: 14 January 2026
Declarations
:
: All participants provided informed consent. Advarra Institutional Review Board (Columbia, MD) reviewed the protocol and survey and provided an exemption for institutional review board oversight.
: DJ is a consultant for Pharming Healthcare, Inc., KalVista Pharmaceuticals, Takeda Pharmaceutical Company, Ltd, CSL Behring, BioCryst Pharmaceuticals, Inc, and Pharvaris; JA is a speakers bureau member for CSL Behring, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc, Takeda Pharmaceutical Company, Ltd, AstraZeneca, and GSK; has received consulting fees from CSL Behring, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc, Pharvaris, Ionis, Takeda Pharmaceutical Company, Ltd, and Novartis AG; and is a clinical trial investigator for BioCryst Pharmaceuticals, Inc, CSL Behring, Pharvaris, KalVista Pharmaceuticals, Astria Therapeutics, Takeda Pharmaceutical Company, Ltd, Novartis AG, and CellDex Therapeutics; SWW received consulting fees from Pharming Healthcare, Inc.; and JRH, NP, AR, PA, AH, and NN are employees of Pharming Healthcare, Inc.
